We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Generate Biomedicines, Inc.
Health Care · Biotechnology
Clinical-stage generative-biology platform - AI-designed protein therapeutics. 3M net), Phase 3 SOLAIRIA-1/2 testing GB-0895 anti-TSLP in severe asthma. $516M cash post-IPO with ~$80M/qtr burn; runway into 1H 2028. 2M quarterly milestone revenue - most platform value remains back-end-loaded.
No key levels recorded for this ticker.